Sana Biotechnology, Inc. (SANA)
| Market Cap | 3.78B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 179.90M |
| EPS (ttm) | -3.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 533,948 |
| Open | 20.16 |
| Previous Close | 20.28 |
| Day's Range | 20.04 - 21.47 |
| 52-Week Range | 16.09 - 44.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2021 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the tr...
Financial Performance
Financial StatementsNews
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy prog...
Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics
Sana Biotechnology has a new $50 million tool in its toolbox.
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to...
Agreement combines Beam's gene editing technology with Sana's ex vivo platform
Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its ...
Sana Biotech To Establish Manufacturing Facility For Gene, Cell Therapy Candidates
Sana Biotechnology Inc (NASDAQ: SANA) has entered into a lease agreement to develop a 163,000 square foot manufacturing facility in Fremont, California. The facility will support the manufacture of San...
Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Pro...
Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies
Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Ste...
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression
Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be present...
Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its p...
Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates
Presented key proof of concept data for multiple platforms at AACR 2021
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes —
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication – – Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tu...
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
Expects to present data at multiple scientific conferences in 2021
Regenerative Medicine Attracted Record $20 Billion in Funding in 2020
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell...
MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, a...
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sh...
SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized...
Sana Announces Upsized Pricing of Initial Public Offering
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its ...
Sana Biotechnology boosts IPO range, looks to raise $517 million
Sana Biotechnology — the Seattle upstart that's looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall…
Sana Biotechnology Sets Terms for $323 Million IPO
The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.
Secretive Sana, still a year away from the clinic, files for an IPO after a mammoth raise
Sana Biotechnology is following the Moderna playbook to a tee: Promise a lot based on very early science, be vague, nab a major VC raise, then gun for an IPO.
Seattle-based Sana Biotechnology aims to raise $150M in IPO
The Seattle-based gene therapy startup filed with the U.S. Securities and Exchange Commission on Wednesday.
Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company's cell-based therapy discovery and...
Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest...